Novo Nordisk pairs with OpenAI

Novo Nordisk said Tuesday it is partnering with OpenAI to use artificial intelligence across drug discovery, manufacturing and medicine delivery. (markets.ft.com) The Danish drugmaker said the deal will use OpenAI tools to analyze large research datasets, spot drug candidates and cut the time from research to patient use. Pilot programs start in research and development, manufacturing and commercial operations, with full integration targeted by the end of 2026. (markets.ft.com) OpenAI will also help train Novo Nordisk’s workforce in artificial intelligence, and the companies said the rollout will include data protection, governance rules and human oversight. Novo Nordisk chief executive Mike Doustdar said the company wants to “test hypotheses faster than ever.” (markets.ft.com) Drug discovery starts with searching huge sets of biology and chemistry data for patterns that might point to a useful target or compound. Drugmakers are also using artificial intelligence in later steps, including picking clinical-trial sites, planning factory output and managing inventories. (cnbc.com) Novo Nordisk is making this push while demand for obesity and diabetes medicines keeps reshaping its business. In 2025, the company reported 82.3 billion Danish kroner in obesity-care sales and 207.1 billion Danish kroner in diabetes-care sales. (annualreport.novonordisk.com) Its 2025 annual report says the company’s value chain runs from identifying new treatments through research and development, manufacturing, supplier partnerships and distribution. That makes the OpenAI deal broader than a lab-only project: it reaches into the parts of the business that decide how quickly medicines get made and shipped. (annualreport.novonordisk.com; markets.ft.com) Investors reacted quickly. Novo Nordisk shares were up 2.8% shortly after the opening bell on April 14, 2026, according to CNBC. (cnbc.com) The partnership also extends Novo Nordisk’s recent artificial-intelligence work with other technology groups. CNBC reported the company already has a collaboration with Nvidia tied to Denmark’s Gefion sovereign artificial-intelligence supercomputer for research and clinical-development use cases. (cnbc.com) Novo Nordisk is due to report first-quarter 2026 results on May 6, 2026. That report will be the next scheduled chance for investors to hear how quickly these pilot programs are moving from announcement to deployment. (novonordisk.com)